Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Publication year range
1.
HLA ; 97(6): 493-504, 2021 06.
Article in English | MEDLINE | ID: mdl-33886161

ABSTRACT

The presence of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) has been recognized as a major risk factor for graft failure (GF) after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide (haplo-PTCy). However, the role of DSAs in salvage haplo-PTCy for rescuing patients with nonmalignant disorders (NMDs) has not yet been reported. The present study retrospectively analyzed 22 patients with NMDs who underwent salvage haplo-PTCy from January 2008 to December 2017. The median age at the time of the rescue haplo-PTCy was 9 years (range, 1-26 years). Median time from the first transplant to second haplo-PTCy was 56 days (range, 37-591 days). Among all patients, six (27.3%) had DSAs, with a median DSA strength (mean fluorescence intensity [MFI]) of 5201 (range, 1412-11,543) in the first DSA testing. In addition, the median DSA MFI was 2672 (range, 832-10,498) before the bone marrow infusion. Overall, GF occurred in 5 (25%) of the 20 assessable patients. Three of four (75%) patients with DSAs experienced GF versus 2 of 16 (12.5%) DSA-negative patients (P = 0.032). The median DSA MFI for patients with GF was 6437 (range, 1412-10,498) versus 1845 (range, 832-2672) for those who engrafted or had early death (P = 0.030). One-year event-free survival was significantly lower in DSA-positive patients than in those without DSAs (16.7% vs. 62.5%, P = 0.002). DSA-negative patients had an acceptable 1-year survival of 62.5%. In conclusion, this study suggests that DSAs may be associated with deleterious outcomes after salvage haplo-PTCy in patients with NMDs.


Subject(s)
Hematopoietic Stem Cell Transplantation , Transplantation Conditioning , Alleles , Cyclophosphamide , Humans , Retrospective Studies
2.
Curitiba; s.n; 2006. XIII-85 p. ilus, tab, graf.
Thesis in Portuguese | LILACS, Sec. Est. Saúde SP, HANSEN, Hanseníase Leprosy, SESSP-ILSLACERVO, Sec. Est. Saúde SP | ID: biblio-1242676

ABSTRACT

Alectina ligante de manose (MBL) e uma proteina com importantepapel na primeira linha de defesa do sistema imune inato, cujos valores sericos sao determinados geneticamente. A MBL ativa a via da lectina do complemento, alem de mediar a opsonisaçao e fagocitose de microorganismos. A hanseniase e uma doença infecciosa cronica causada pelo Mycobacterium leprae, bacteria intracelular obrigatoria, que infecta fagocitos mononucleares do ospedeiro...


Subject(s)
Humans , Leprosy/physiopathology , Leprosy/immunology , Leprosy/microbiology , Lectins/physiology , Lectins/immunology , Mycobacterium leprae/cytology , Mycobacterium leprae/physiology , Mycobacterium leprae/immunology , Dolichol Monophosphate Mannose , Dolichol Monophosphate Mannose/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...